Region — International. Neutral scientific reference — not offered for sale here.

Set region

Explore Shop Tools Journal Trust

Explore  /  Eloralintide

Research reference — not for sale

Eloralintide

B

lead outcome

Weight loss / obesity

grades vary by outcome ↓

Peptide

also called — Eloralintide · LY3841136 (Lilly development code)

weight management / obesityselective amylin-receptor agonism (satiety)cardiometabolic improvementcombination-ready (with incretins)

The amylin that hit incretin-level weight loss — and rewrote the class's market lesson. Eloralintide (Lilly) closes the register's amylin lineage on a high note, and it comes with a genuinely beautiful backstory. Three threads: (1) the amylin origin story — the whole class descends from a mysterious "junk" amyloid found clogging diabetics' pancreases for a century, which turned out to be a third islet hormone; (2) eloralintide is a selective amylin-receptor agonist that delivered up to ~20% weight loss in Phase 2 — matching tirzepatide-class numbers without an incretin mechanism; (3) landing weeks after Petrelintide (#69), it flips that entry's lesson: amylins can reach top-tier efficacy, so magnitude — not just tolerability — is now in play for the class. Straight to Phase 3.

In brief

Eloralintide (Lilly's LY3841136) is a once-weekly, selective amylin-receptor agonist — and it closes the register's amylin story with the class's strongest monotherapy data yet. The amylin lineage has a lovely origin: the hormone was discovered as the mysterious amyloid "junk" clogging diabetics' pancreases for a century, which turned out to be a third islet hormone that signals fullness (co-secreted with insulin). Eloralintide's Phase 2 (Lancet, 2025) delivered up to ~20% mean weight loss over 48 weeks (range 9.5–20.1% vs 0.4% placebo) — incretin-class numbers from a non-incretin mechanism — with generally good tolerability (GI/fatigue AEs dose-dependent; placebo-like at lower doses). That result matters beyond the drug: arriving just after Petrelintide (#69) — whose ~10.7% disappointed the market — eloralintide shows the amylin class can reach the top tier, so efficacy magnitude, not just tolerability, is the real battleground. Lilly went straight to Phase 3 and is testing an eloralintide + tirzepatide combination. The honest read: a standout Phase 2 for a selective amylin agonist — high efficacy, good tolerability — but still investigational, Phase 3 pending, and (as Petrelintide showed) mid-stage promise isn't approval.

Legal standing, by region

European Union

Not FDA-approved (gray-market)

investigational; not approved. Phase 2 complete → Phase 3 enrolling (obesity). A well-capitalized Lilly clinical program, not a gray-market compound.

Evidence, by outcome

How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade

Weight loss / obesity

Standout Phase 2 — highest amylin-monotherapy weight loss reported — but not yet Phase 3-confirmed; predominantly female cohort (78%)

Phase 2, Lancet 2025 (263 pts, 48 wk): up to 20.1% (−21.3 kg) vs 0.4% placebo; dose-dependent; Phase 1 ~11%/12 wk

B

Tolerability

Strong — but the highest-efficacy (highest-dose) arms had more AEs; escalation protocol matters

GI + fatigue AEs, dose-dependent; similar to placebo at; slower escalation helped

A

Cardiometabolic risk factors

Consistent secondary benefits; Phase 2 level

Improvements in waist, BP, lipids, glycemia, inflammation

B

Combination with tirzepatide

No combination efficacy data yet

Trial ongoing (LY3841136 + tirzepatide)

—

Safety

No unexpected signals; investigational — Phase 3/long-term safety pending

Phase 2 (263) + Phase 1

B

Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Eloralintide changes - nothing else.

Identity

a synthetic, selective agonist of the amylin receptor, engineered for once-weekly subcutaneous dosing, from Eli Lilly. Lilly emphasizes "molecule specificity" — eloralintide is designed to hit the amylin receptor cleanly/selectively (rather than a broad multi-receptor sweep), the company's bet on precision within this class.

Mechanism (as proposed)

like all amylins, eloralintide engages amylin receptors (AMY = calcitonin receptor + RAMP) concentrated in the hindbrain area postrema / NTS and hypothalamic circuits, producing satiety, delayed gastric emptying, and glucagon suppression — making people eat less and feel full sooner. Its distinguishing design is selectivity for the amylin receptor (Lilly's "molecule specificity" thesis), aiming for a clean amylin signal. Because this pathway is entirely separate from GLP-1/GIP incretins, it can serve as an alternative (for people who don't tolerate incretins) or a complement (stacked with tirzepatide). As with the whole class, the molecule is engineered to avoid the amyloid fibrillation that makes native amylin toxic — the direct legacy of amylin's "discovered-as-toxic-amyloid" origin.

Chemical identifiers

Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.

PubChem CID175663130

InChIKeyRLBIFQNAUXZCQB-UHFFFAOYSA-N

SMILESCC1C(=O)NC(C(=O)NC(CSCSCC(C(=O)NC(C(=O)NC(C(=O)N1)C(C)O)CC(=O)N)NC(=O)CCC(C(=O)O)N)C(=O)NC(C)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(CCCN)C(=O)NC(CC(C)C)C(=O)NC(C)C(=O)NC(CCC(=O)O)C(=O)NC(C)(CC2=CC=CC=C2)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)N(C)C(CC(=O)N)C(=O)NC(CC3=CC=CC=C3)C(=O)NCC(=O)N4CCCC4C(=O)NC(CCCCNC(=O)CCC(C(=O)O)NC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)NC(CC(C)C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(C(C)O)C(=O)NC(CCC(=O)O)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC7=CC=C(C=C7)O)C(=O)N)C(C)O

via PubChem exact-name match (Eloralintide) · high confidence

Sources — 4 cited

01Bailey et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2… trial. The Lancet, 2025 (NCT06230523; up to 20.1% / −21.3 kg vs 0.4% placebo; tolerability).

02Eli Lilly press release (6 Nov 2025): Phase 2 results; 9.5–20.1% weight loss; cardiometabolic improvements; Phase 3 enrollment beginning; "molecule specificity" (Kenneth Custer).

03Amylin discovery/history: Cooper GJ et al. PNAS 1987; Westermark P et al. 1986–1987 (IAPP isolation from islet amyloid); "islet hyalinization" 1900 → amyloid identification → third islet hormone; fibrillation/toxicity → engineered non-aggregating analogs.

04Combination study: LY3841136 + tirzepatide (ClinicalTrials.gov). (Investigational; not approved as of 2026.)

Updated 2026-07-13 (Phase 3 obesity enrolling; eloralintide + tirzepatide combination and Phase 3 readouts are the catalysts — and the real test of whether ~20% holds at scale)

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds

Pramlintide (Symlin)A

Explore by goal

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

Region — International

ExploreRegister The Register — full index Categories Trust & COA How we grade Open data Brands

ShopCosmetic peptides Journal Quizzes

TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.